Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in Mild to Moderate Systemic Lupus Erythematosus
CTR20192659Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in systemic lupus erythematosus (SLE), sponsored by InnoCare Pharma. Started Dec 2019; status: completed.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20192659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192659.